Unlabelled: Parkinson's disease is one of the most common progressive neurodegenerative diseases of the brain, usually leading to significant disability. Rehabilitation, in addition to symptomatic pharmacotherapy, should be the mainstay of treatment for each patient. The aim of this study was to collect data on the use of different methods of rehabilitation treatment for patients with Parkinson's disease living in the area of Bialystok (before 1998 the province of Bialystok) and evaluation of environmental, social and health factors, which affect the use of this form of treatment.

Material And Methods: We evaluated patients with Parkinson's disease treated in neurological departments in Bialystok and Choroszcz near Bialystok over the next 12 months. It was conducted using a specially constructed for this purpose questionnaire. The course of Parkinson's disease was also assessed in the Hoehn and Yahr and the Schwab and England scale.

Results: We have studied 88 patients with clinical diagnosis of Parkinson's disease (48 women and 40 men), mean age 68.7 years. It was found that only 73% of those surveyed had ever been rehabilitated. In 27% of patients had never been used any rehabilitation treatment. It was shown that the level of education positively influences the use of rehabilitation, while the coexistence of additional diseases, living in the country and the older age impede the use of physiotherapy. The stage of disease and sex of patients did not affect the use of rehabilitation. Patients were primarily rehabilitated in a hospital. Among the most commonly used treatments were kinesis therapy, massage and hydrotherapy.

Conclusions: The study indicates too low access of patients with Parkinson's disease to rehabilitation and confirms purposefulness of initiating information and education action about the need for physiotherapy treatment in these group of patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

parkinson's disease
28
patients parkinson's
16
disease
8
disease living
8
rehabilitation treatment
8
patients
8
parkinson's
7
rehabilitation
6
[rehabilitation patients
4
living region
4

Similar Publications

Searching for new drugs to treat Alzheimer's disease dementia through multiple pathways.

World J Clin Cases

January 2025

Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.

Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.

View Article and Find Full Text PDF

This study aimed to evaluate different combinations of three dietary supplements for potential additive or synergistic effects in an Parkinson's Disease model. The complex and diverse processes leading to neurodegeneration in each patient with a neurodegenerative disorder cannot be effectively addressed by a single medication. Instead, various combinations of potentially neuroprotective agents targeting different disease mechanisms simultaneously may show improved additive or synergistic efficacy in slowing the disease progression and allowing the agents to be utilized at lower doses to minimize side effects.

View Article and Find Full Text PDF

Targeting cardiolipin metabolism for Parkinson's disease therapy.

Metabol Open

December 2024

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a neurodegenerative disorder that significantly impacts patients' quality of life. Managing PD requires accurate assessment of motor and non-motor symptoms, often complicated by the subjectivity in symptom reporting and the limited availability of neurologists. To address these challenges, commercial wearable devices have emerged to continuously monitor PD symptoms outside the clinical setting.

View Article and Find Full Text PDF

Background: Interest in wearable device use in Parkinson's disease (PD) has grown rapidly with many compelling studies supporting diagnostic and therapeutic uses. Concurrently, consumer devices have proliferated and their role in health and wellness has expanded. However, incorporation of consumer and medical wearable devices into medical care has in our experience been limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!